Ophthotech Shares Up 6% Amid Notable Buying in Dec. $40 Calls, Volume of 300 at $10.30; BZ NOTE: Traders Betting on ~30% Upside in Stock Over Next Three Weeks, Results from Phase 3 Trial of Fovista Expected Before Year End